Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance

The aim of this study was to compare response rates and survival in women with “platinum resistant” epithelial ovarian cancer (EOC) who received further platinum-based or non‑platinum chemotherapy for treatment at first relapse. Patients with high-grade EOC (including fallopian tube and peritoneal c...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2018-08, Vol.150 (2), p.239-246
Main Authors: Lindemann, Kristina, Gao, Bo, Mapagu, Cristina, Fereday, Sian, Emmanuel, Catherine, Alsop, Kathryn, Traficante, Nadia, Harnett, Paul R., Bowtell, David D.L., deFazio, Anna
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Ovarian Epithelial
Chemotherapy response
Cohort Studies
Drug Resistance, Neoplasm
Female
Humans
Middle Aged
Neoplasms, Glandular and Epithelial - drug therapy
Neoplasms, Glandular and Epithelial - pathology
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - therapeutic use
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Platinum-free interval
Platinum-resistant
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to compare response rates and survival in women with “platinum resistant” epithelial ovarian cancer (EOC) who received further platinum-based or non‑platinum chemotherapy for treatment at first relapse. Patients with high-grade EOC (including fallopian tube and peritoneal cancer) of all histologies recruited to the Australian Ovarian Cancer Study (AOCS) and treated with platinum-based primary chemotherapy were included. Response to second-line chemotherapy, overall survival (OS) and survival after treatment for first progression (OS2) were determined in all histologies and separately in women with high-grade serous tumors. Of the 341 patients classified as platinum-resistant by the 6-month threshold, 243 (71%) were treated with chemotherapy at relapse. CA-125 response rates to platinum-based chemotherapy were significantly higher compared to non‑platinum chemotherapy (51% vs 21%, P 
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2018.05.020